The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

With improved understanding of the biology of differentiated thyroid carcinoma its
management is evolving. The approach to surgery for the primary tumour and elective nodal …

Background Both radioactive iodine (RAI) and external beam radiation therapy (EBRT) offer
important clinical benefits in properly selected patients with differentiated thyroid cancer …

Management recommendations for differentiated thyroid cancer are evolving. Total
thyroidectomy is the backbone of curative-intent therapy, with radioiodine ablation (RAI) of …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and the fifth
most common cancer in women. DTC therapy requires a multimodal approach, including …

Background: Radioactive iodine (RAI) remnant ablation has been used to eliminate normal
thyroid tissue and may also facilitate monitoring for persistent or recurrent thyroid carcinoma …

The incidence of differentiated thyroid cancer has increased worldwide over the last three
decades, but thyroid cancer-related mortality remains stable. Until recently, the standard …

A remarkable, evidence-based trend toward de-escalation has reformed the practice of
radioactive iodine (RAI) administration for thyroid cancer patients. Updated guidelines have …

Differentiated thyroid carcinomas are typically treated with total thyroidectomy as initial
therapy. Subsequent radioactive iodine (RAI) ablation destroys post-surgical thyroid …

Differentiated thyroid cancers are typically iodine-avid and can be effectively treated with
radioiodine. In most patients, radioiodine treatment is done for ablation of residual tissue …